Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo

Journal of Radiation Research

Volumn 48, Issue 5, 2007, Pages 351-360

  Colquhoun, A J ^a   Mchugh, L A ^a   Tulchinsky, E ^a   Kriajevska, M ^a   Mellon, J K ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Invasive bladder cancer; Radiosensitizing agents; Radiotherapy; Tyrosine kinase inhibitors

Indexed keywords

AMINO ACIDS; CELLS; CHEMICAL ACTIVATION; CYTOLOGY; DIAGNOSIS; DISEASES; IONIZING RADIATION; MUSCLE; TUMORS;

BLADDER CANCER CELLS; BLADDER CANCERS; BLADDER TUMOR; EPIDERMAL GROWTH FACTOR RECEPTORS; GEFITINIB; IN-VITRO; INVASIVE BLADDER CANCER; MONO-THERAPY; RADIOSENSITIZING AGENT; TYROSINE KINASE INHIBITOR;

RADIOTHERAPY;

MURINAE;

EID: 34548862576     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.07014     Document Type: Article

References (22)

1. Cancer Research UK, CancerStats monograph 2004.
2. Chang, S. S., Cookson, M. S., Baumgartner, R. G., Wells, N. and Smith, J. A. Jr. (2002). Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J. Urol. 167: 2012-2016.
3. Duncan, W. and Quilty, P. M. (1986). The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother. Oncol. 7: 299-310.
4. Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A. C., Boyd, S., Skinner, E., Bochner, B., Thangathurai, D., Mikhail, M., Raghavan, D. and Skinner, D. G. (2001). Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1,054 patients. J. Clin. Oncol. 19: 666-675.
5. Skinner, D. G., Lieskowsky, G. and Boyd, S. D. (1988). Continent Urinary Diversion. A 5 1/2-yr experience. Ann. Surg. 208: 337-344.
6. Neal, D. E., Marsh, C., Bennett, M. K., Abel, P. D., Hall, R. R., Sainsbury, J. R. and Harris, A. L. (1985). Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. i: 366-368.
7. Mellon, J. K., Wright, C., Kelly, P., Horne, C. H. and Neal, D. E. (1995). Long-term outcome related to EGFR status in bladder cancer. J. Urol. 153: 919-925.
8. Schmidt-Ullrich, R. K., Valerie, K., Fogleman, B. and Walters, J. (1996). The radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat. Res. 145: 81-85.
9. Dent, P., Reardon, D. B., Park, J. S., Bowers, G., Logsdon, C., Valerie, K. and Schmidt-Ullrich, R. K. (1999). Radiation-induced release of TGFα activates the epidermal growth factor receptor and MAPK pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol. Biol. Cell. 10: 2493-2506.
10. Fry, D. W. (2003). Mechanism of action of erbB tyrosine kinase inhibitors. Exp. Cell. Res. 284: 131-139.
11. Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., Von Pawel, J., Pluzanska, A., Gatzemeier, U., Grous, J., Ochs, J. S., Averbuch, S. D., Wolf, M. K., Rennie, P., Fandi, A. and Johnson, D. H. (2004). Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22: 777-784.
12. Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., Wolf, M. K., Krebs, A. D., Averbuch, S. D., Ochs, J. S., Grous, J., Fandi, A. and Johnson, D. H. (2004). Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22: 785-794.
13. Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., Ove, R., Kies, M. S., Baselga, J., Youssoufian, H., Amellal, N., Rowinsky, E. K. and Ang, K. K. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354: 567-578.
14. Bridges, A. J. (2001). Chemical inhibitors of protein kinases. Chem. Rev. 100: 2541-2572.
15. Li, Z., Hosoi, Y., Cai, K., Tanno, Y., Matsumoto, Y., Enomoto, A., Morita, A., Nakagawa, K. and Miyagawa, K. (2006). Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation. Biochem. Biophys. Res. Commun. 341: 363-368.
16. Meye, A., Fiedler, U. and Kunert, A. (2001). Growth inhibitory effects of ZD 1839 ('Iressa') on human bladder cancer cell lines. Proc. Am. Assoc. Cancer. Res. 42: 805.
17. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R. and Tortora, G. (2000). Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer. Res. 6: 2053-2063.
18. Maddineni, S. B., Sangar, V. K., Hendry, J. H., Margison, G. P. and Clarke, N. W. (2005). Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br. J. Cancer. 92: 125-130.
19. Dominguez-Escrig, J. L., Kelly, J. D., Neal, D. E., King, S. M. and Davies, B. R. (2004). Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin. Cancer. Res. 10: 4874-4884.
20. Huang, S. M., Li, J., Armstrong, E. A. and Harari, P. M. (2002). Modulation of radiation response and tumour-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer. Res. 62: 4300-4306.
21. Lammering, G., Valerie, K., Peck-sun, L., Mikkelsen, R. B., Contessa, J. N., Feden, J. P., Farnsworth, J., Dent, P. and Schmidt-Ullrich, R. K. (2001). Radiosensitisation of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin. Cancer. Res. 7: 682-690.
22. Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J. and Gibson, K. H. (2002). ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer. Res. 62: 5749-5754.